Phase 3 Psoriasis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- The child or teen must be between 6 and 17 years old (inclusive) at the time of signing the consent forms
- They must have been diagnosed with moderate to severe plaque psoriasis for at least 3 months before the screening visit
- At both the screening and baseline appointments, psoriasis must cover at least 10% of the body's surface area, have a disease severity score of 3 or higher (out of 4), and have a psoriasis severity score of 12 or higher — or a score of 10 or higher plus psoriasis affecting the face, genitals, or hands and feet in a meaningful way
- They must be a suitable candidate for systemic psoriasis treatment (medication that works throughout the whole body) and/or light therapy, and eligible for a specific medication called ustekinumab
- They must weigh at least 15 kg (about 33 lbs) and have a body mass index (a measure of body size) at or above the 5th percentile for their age
Who may not be able to join:
- Those who tried one or more specific biologic medications targeting IL-17 (such as brodalumab, ixekizumab, or secukinumab) without any improvement within 12 weeks, or who had no response to more than one biologic medication of a different type
- Those who have a type of psoriasis other than plaque psoriasis (such as guttate, pustular, or erythrodermic), or another skin condition that could make it hard to assess the psoriasis
- Those who have a history of, or symptoms suggesting, inflammatory bowel disease (a long-term condition causing inflammation in the digestive tract)
- Those with a history of active tuberculosis (TB) that was not successfully treated, or latent (inactive) TB that was not treated with preventive medication
- Those who have a current serious infection or a history of serious, long-lasting, or unusual infections
- Those who have previously received the study drug bimekizumab
- Those who have previously received ustekinumab
- Those who have taken certain other medications outside of the allowed timeframes, or are currently taking treatments that are not permitted in this trial (confirm with trial site)
- Those who currently have active thoughts of suicide or a history of suicidal behaviour
- Those who have been diagnosed with severe depression in the 6 months before the screening visit
- Those who have been admitted to a psychiatric hospital within the past year before joining the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: UCB Cares, 001 844 599 2273
Phone: 1-844-599-2273 (USA)
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Psoriasis Area Severity Index 90 (PASI90) response at Week 16; Investigator´s Global Assessment (IGA) 0/1 response at Week 16
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.